Gast ::
| Hauptseite > Publikationsdatenbank > [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer > print |
| Hauptseite > Publikationsdatenbank > [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer > print |
| 001 | 893306 | ||
| 005 | 20250813093259.0 | ||
| 024 | 7 | _ | |2 doi |a 10.1007/s11307-020-01546-0 |
| 024 | 7 | _ | |2 ISSN |a 1536-1632 |
| 024 | 7 | _ | |2 ISSN |a 1860-2002 |
| 024 | 7 | _ | |2 Handle |a 2128/28068 |
| 024 | 7 | _ | |2 pmid |a 33006028 |
| 024 | 7 | _ | |2 WOS |a WOS:000574311700001 |
| 037 | _ | _ | |a FZJ-2021-02680 |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |0 P:(DE-HGF)0 |a Dietlein, Felix |b 0 |
| 245 | _ | _ | |a [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer |
| 260 | _ | _ | |a Cham |b Springer Nature Switzerland |c 2021 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1625900993_16098 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 520 | _ | _ | |a Purpose: PSMA imaging is frequently used for monitoring of androgen deprivation therapy(ADT) in prostate cancer. In a previous study, [18F]-JK-PSMA-7 exhibited favorable propertiesfor tumor localization after biochemical recurrence. In this retrospective study, we evaluated theperformance of [18F]-JK-PSMA-7 under ADT.Procedures: We examined the performance of [18F]-JK-PSMA-7 in 70 patients (first cohort) withincreasing or detectable PSA values under ADT (PSA G 2 ng/ml for 21/70 patients). We furtheranalyzed 58 independent patients with PSA levels G 2 ng/ml under ADT, who were imaged with[68Ga]PSMA-11 or [18F]DCFPyL (second cohort). Finally, we compared detection rates between[18F]-JK-PSMA-7, [68Ga]PSMA-11, and [18F]DCFPyL.Results: In the first cohort, we detected [18F]-JK-PSMA-7-positive lesions in 63/70 patients. Inpatients with PSA levels ≥ 2 ng/ml, the detection rate was 100 % (49/49). In patients with PSA G 2ng/ml, the detection rate was significantly lower (66.7 %, 14/21, p = 9.7 × 10−5) and dropped from85.7%(12/14, PSA levels between 0.3 and 2.0 ng/ml) to 28.6%(2/7) for PSA levels G 0.3 ng/ml (p =1.73 × 10−2). In the second cohort (PSA G 2 ng/ml), the detection rate was 79.3 % (46/58) for[68Ga]PSMA-11 or [18F]DCFPyL. Again, the detection rate was significantly higher (p = 1.1 × 10−2)for patients with PSA levels between 0.3 and 2.0 ng/ml (87.0 %, 40/46) relative to those with PSAlevels G 0.3 ng/ml (50 %, 6/12). No significant difference was found between [18F]-JK-PSMA-7 and[68Ga]PSMA-11 or [18F]DCFPyL in patients with PSA levels G 2 ng/ml (p = 0.4295).Conclusion: [18F]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels ≥0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates wasconsistent across the three PSMA ligands. Thus, PSMA imaging is suitable for clinical follow-upof patients with increasing PSA levels under ADT. |
| 536 | _ | _ | |0 G:(DE-HGF)POF4-525 |a 525 - Decoding Brain Organization and Dysfunction (POF4-525) |c POF4-525 |f POF IV |x 0 |
| 542 | _ | _ | |2 Crossref |i 2020-10-01 |u https://creativecommons.org/licenses/by/4.0 |
| 542 | _ | _ | |2 Crossref |i 2020-10-01 |u https://creativecommons.org/licenses/by/4.0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Mueller, Peter |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Kobe, Carsten |b 2 |
| 700 | 1 | _ | |0 P:(DE-Juel1)180330 |a Endepols, Heike |b 3 |u fzj |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Hohberg, Melanie |b 4 |
| 700 | 1 | _ | |0 P:(DE-Juel1)185610 |a Zlatopolskiy, Boris |b 5 |u fzj |
| 700 | 1 | _ | |0 P:(DE-Juel1)169356 |a Krapf, Philipp |b 6 |u fzj |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Heidenreich, Axel |b 7 |
| 700 | 1 | _ | |0 P:(DE-Juel1)166419 |a Neumaier, Bernd |b 8 |u fzj |
| 700 | 1 | _ | |0 P:(DE-Juel1)177611 |a Drzezga, Alexander |b 9 |u fzj |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Dietlein, Markus |b 10 |e Corresponding author |
| 773 | 1 | 8 | |2 Crossref |3 journal-article |a 10.1007/s11307-020-01546-0 |b Springer Science and Business Media LLC |d 2020-10-01 |n 2 |p 277-286 |t Molecular Imaging and Biology |v 23 |x 1536-1632 |y 2020 |
| 773 | _ | _ | |0 PERI:(DE-600)2079211-6 |a 10.1007/s11307-020-01546-0 |g Vol. 23, no. 2, p. 277 - 286 |n 2 |p 277-286 |t Molecular imaging and biology |v 23 |x 1536-1632 |y 2021 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/893306/files/Dietlein2021_Article_%5B18F%5D-JK-PSMA-7PETCTUnderAndro.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:893306 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)180330 |a Forschungszentrum Jülich |b 3 |k FZJ |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)185610 |a Forschungszentrum Jülich |b 5 |k FZJ |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)169356 |a Forschungszentrum Jülich |b 6 |k FZJ |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)166419 |a Forschungszentrum Jülich |b 8 |k FZJ |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)177611 |a Forschungszentrum Jülich |b 9 |k FZJ |
| 913 | 1 | _ | |0 G:(DE-HGF)POF4-525 |1 G:(DE-HGF)POF4-520 |2 G:(DE-HGF)POF4-500 |3 G:(DE-HGF)POF4 |4 G:(DE-HGF)POF |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |v Decoding Brain Organization and Dysfunction |x 0 |
| 913 | 0 | _ | |0 G:(DE-HGF)POF3-573 |1 G:(DE-HGF)POF3-570 |2 G:(DE-HGF)POF3-500 |3 G:(DE-HGF)POF3 |4 G:(DE-HGF)POF |a DE-HGF |b Key Technologies |l Decoding the Human Brain |v Neuroimaging |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0600 |2 StatID |a DBCoverage |b Ebsco Academic Search |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b MOL IMAGING BIOL : 2018 |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0113 |2 StatID |a WoS |b Science Citation Index Expanded |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)3002 |2 StatID |a DEAL Springer |d 2020-10-13 |w ger |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)9900 |2 StatID |a IF < 5 |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0510 |2 StatID |a OpenAccess |
| 915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer Review |b ASC |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0160 |2 StatID |a DBCoverage |b Essential Science Indicators |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |d 2020-10-13 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Clarivate Analytics Master Journal List |d 2020-10-13 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| 999 | C | 5 | |1 M Dietlein |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s11307-015-0866-0 |p 575 - |t Mol Imaging Biol |u Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575–584 |v 17 |y 2015 |
| 999 | C | 5 | |1 F Dietlein |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.116.185538 |p 947 - |t J Nucl Med |u Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M (2017) PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med 58:947–952 |v 58 |y 2017 |
| 999 | C | 5 | |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.119.234898 |u Dietlein F, Kobe C, Hohberg M et al (2020) Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA-PET imaging in patients with relapsed prostate cancer. J Nucl Med 61:729–734 |
| 999 | C | 5 | |1 FL Giesel |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-016-3573-4 |p 678 - |t Eur J Nucl Med Mol Imaging |u Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C (2017) F-19 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688 |v 44 |y 2017 |
| 999 | C | 5 | |1 BD Zlatopolskiy |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.118.218495 |p 817 - |t J Nucl Med |u Zlatopolskiy BD, Endepols H, Krapf P, Guliyev M, Urusova EA, Richarz R, Hohberg M, Dietlein M, Drzezga A, Neumaier B (2019) Discovery of 18F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions. J Nucl Med 60:817–823 |v 60 |y 2019 |
| 999 | C | 5 | |2 Crossref |9 -- missing cx lookup -- |a 10.1186/s13550-019-0540-7 |u Hohberg M, Dietlein M, Kobe C et al (2019) Biodistribution and radiation dosimetry of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. Ejnmmi Res 9(1):66. https://doi.org/10.1186/s13550-019-0540-7 |
| 999 | C | 5 | |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.119.229542 |u Dietlein F, Hohberg M, Kobe C et al (2020) An 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer: first-in-humans observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application. J Nucl Med 61:202–209 |
| 999 | C | 5 | |2 Crossref |u Morret N, van den Bergh RCN, Briers E et al (2018) EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. European Association of Urology 2018; uroweb.org; last access on 2019, Oct 09 |
| 999 | C | 5 | |2 Crossref |9 -- missing cx lookup -- |a 10.1158/1078-0432.CCR-19-1050 |u Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron-emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res in press. https://doi.org/10.1158/1078-0432.CCR-19-1050 |
| 999 | C | 5 | |1 L Emmett |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.118.223099 |p 950 - |t J Nucl Med |u Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O’Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM (2019) Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60:950–954 |v 60 |y 2019 |
| 999 | C | 5 | |1 A Afshar-Oromieh |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-018-4079-z |p 2045 - |t Eur J Nucl Med Mol Imaging |u Afshar-Oromieh A, Debus N, Uhrig M et al (2019) Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 45:2045–2054 |v 45 |y 2019 |
| 999 | C | 5 | |1 C Leitsmann |2 Crossref |9 -- missing cx lookup -- |a 10.1590/s1677-5538.ibju.2018.0305 |p 459 - |t Int Braz J Urol |u Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, Trojan L, Strauss A (2019) Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases? Int Braz J Urol 45:459–467 |v 45 |y 2019 |
| 999 | C | 5 | |1 M Eiber |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.117.198119 |p 469 - |t J Nucl Med |u Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 59:469–478 |v 59 |y 2018 |
| 999 | C | 5 | |1 SP Rowe |2 Crossref |9 -- missing cx lookup -- |a 10.2967/jnumed.117.195255 |p 479 - |t J Nucl Med |u Rowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med 59:479–485 |v 59 |y 2018 |
| 999 | C | 5 | |1 F Ceci |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-019-04505-2 |p 136 - |t Eur J Nucl Med Mol Imaging |u Ceci F, Bianch L, Borghesi et al (2020) Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment of prostate cancer. Eur J Nucl Med Mol Imaging 47:136–146 |v 47 |y 2020 |
| 999 | C | 5 | |1 C Onal |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-019-04581-4 |p 632 - |t Eur J Nucl Med Mol Imaging |u Onal C, Guler OC, Torun N, Reyhan M, Yapar AF (2020) The effect of androgen deprivation on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging 47:632–641 |v 47 |y 2020 |
| 999 | C | 5 | |1 O Ettala |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-019-04635-7 |p 665 - |t Eur J Nucl Med Mol Imaging |u Ettala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, Kemppainen J (2020) Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging 47:665–673 |v 47 |y 2020 |
| 999 | C | 5 | |1 M Wondergem |2 Crossref |9 -- missing cx lookup -- |a 10.1097/RLU.0000000000002585 |p 582 - |t Clin Nucl Med |u Wondergem M, van der Zant F, Broos W, Knol R (2019) Increased PSMA expression in castration-resistant prostate cancer metastases 3 months after initiation of enzalutamide indicated by 18F-DCFPyL PET/CT. Clin Nucl Med 44:582–584 |v 44 |y 2019 |
| 999 | C | 5 | |1 F Rosar |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-019-04674-0 |p 687 - |t Eur J Nucl Med Mol Imaging |u Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S (2020) New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castrate-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging 47:687–694 |v 47 |y 2020 |
| 999 | C | 5 | |1 S Vaz |2 Crossref |9 -- missing cx lookup -- |a 10.1007/s00259-019-04529-8 |p 9 - |t Eur J Nucl Med Mol Imaging |u Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging 47:9–15 |v 47 |y 2020 |
| 999 | C | 5 | |1 ID Davis |2 Crossref |9 -- missing cx lookup -- |a 10.1056/NEJMoa1903835 |p 121 - |t N Engl J Med |u Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2019) Enzalutamide with standrad first-line therapy in metastastic prostate cancer. N Engl J Med 381:121–131 |v 381 |y 2019 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|